Aging- and Tumor-Mediated Increase in CD8+CD28− T Cells Might Impose a Strong Barrier to Success of Immunotherapy in Glioblastoma

Abstract excerpt

Abstract Clinical use of various forms of immunotherapeutic drugs in glioblastoma (GBM), has highlighted severe T cell dysfunction such as exhaustion in GBM patients. However, reversing T cell exhaustion using immune checkpoint inhibitors in GBM clinical trials has not shown significant overall survival benefit. Phenotypically, CD8+ T cells with downregulated CD28 coreceptors, low CD27 expression, increased CD57...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Immunotherapy and Immune Responses
• Share to T-cell and B-cell Immunology